Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome

Anna Richards, M. Kathryn Liszewski, David Kavanagh, Celia J. Fang, Elizabeth Moulton, Veronique Fremeaux-Bacchi, Giuseppe Remuzzi, Marina Noris, Timothy H J Goodship, John P. Atkinson

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The hemolytic uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. There are two general types. One occurs in epidemic form and is diarrheal associated (D + HUS). It has a good prognosis. The second is a rare form known as atypical (aHUS), which may be familial or sporadic, and has a poor prognosis. aHUS is increasingly recognized to be a disease of defective complement regulation, particularly cofactor activity. Mutations in membrane cofactor protein (MCP; CD46) that predispose to the development of aHUS were first identified in 2003. MCP is a membrane-bound complement regulator that acts as a cofactor for the factor I-mediated cleavage of C3b and C4b deposited on host cells. More than 20 different mutations in MCP have now been identified in patients with aHUS. Many of these mutants have been functionally characterized and have helped to define the pathogenic mechanisms leading to aHUS development. Over 75% of the reported mutations cause a reduction in MCP expression, due to homozygous, compound heterozygous or heterozygous mutations. This deficiency of MCP leads to inadequate control of complement activation on endothelial cells after an initiating injury. The remaining MCP mutants are expressed, but demonstrate reduced ligand (C3b/C4b) binding capacity and cofactor activity of MCP. MCP mutations in aHUS demonstrate incomplete penetrance, indicating that additional genetic and environmental factors are required to manifest disease. MCP mutants as a cause of aHUS have a favorable clinical outcome in comparison to patients with factor H (CFH) or factor I (IF) mutations. In 90% of the renal transplants performed in patients with MCP-HUS, there has been no recurrence of the primary disease, whilst >50% of factor I or factor H deficient patients have had a prompt recurrence. This highlights the importance of defining and characterizing the underlying genetic defects in patients with aHUS.

Original languageEnglish
Pages (from-to)111-122
Number of pages12
JournalMolecular Immunology
Volume44
Issue number1-3
DOIs
Publication statusPublished - Jan 2007

Fingerprint

CD46 Antigens
Mutation
Complement Factor H
Recurrence
Hemolytic-Uremic Syndrome
Penetrance
Complement Activation
Hemolytic Anemia
Acute Kidney Injury
Thrombocytopenia
Atypical Hemolytic Uremic Syndrome
Endothelial Cells
Ligands
Transplants
Kidney
Membranes
Wounds and Injuries

Keywords

  • Alternative pathway of complement (AP)
  • Atypical hemolytic uremic syndrome (aHUS)
  • CD46)
  • Cofactor activity (CA)
  • Complement factor H (CFH)
  • Factor I (IF)
  • Membrane cofactor protein (MCP
  • Renal transplantation

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Richards, A., Kathryn Liszewski, M., Kavanagh, D., Fang, C. J., Moulton, E., Fremeaux-Bacchi, V., ... Atkinson, J. P. (2007). Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Molecular Immunology, 44(1-3), 111-122. https://doi.org/10.1016/j.molimm.2006.07.004

Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. / Richards, Anna; Kathryn Liszewski, M.; Kavanagh, David; Fang, Celia J.; Moulton, Elizabeth; Fremeaux-Bacchi, Veronique; Remuzzi, Giuseppe; Noris, Marina; Goodship, Timothy H J; Atkinson, John P.

In: Molecular Immunology, Vol. 44, No. 1-3, 01.2007, p. 111-122.

Research output: Contribution to journalArticle

Richards, A, Kathryn Liszewski, M, Kavanagh, D, Fang, CJ, Moulton, E, Fremeaux-Bacchi, V, Remuzzi, G, Noris, M, Goodship, THJ & Atkinson, JP 2007, 'Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome', Molecular Immunology, vol. 44, no. 1-3, pp. 111-122. https://doi.org/10.1016/j.molimm.2006.07.004
Richards, Anna ; Kathryn Liszewski, M. ; Kavanagh, David ; Fang, Celia J. ; Moulton, Elizabeth ; Fremeaux-Bacchi, Veronique ; Remuzzi, Giuseppe ; Noris, Marina ; Goodship, Timothy H J ; Atkinson, John P. / Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. In: Molecular Immunology. 2007 ; Vol. 44, No. 1-3. pp. 111-122.
@article{cd4c659620424dc983202c49a9c3a5da,
title = "Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome",
abstract = "The hemolytic uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. There are two general types. One occurs in epidemic form and is diarrheal associated (D + HUS). It has a good prognosis. The second is a rare form known as atypical (aHUS), which may be familial or sporadic, and has a poor prognosis. aHUS is increasingly recognized to be a disease of defective complement regulation, particularly cofactor activity. Mutations in membrane cofactor protein (MCP; CD46) that predispose to the development of aHUS were first identified in 2003. MCP is a membrane-bound complement regulator that acts as a cofactor for the factor I-mediated cleavage of C3b and C4b deposited on host cells. More than 20 different mutations in MCP have now been identified in patients with aHUS. Many of these mutants have been functionally characterized and have helped to define the pathogenic mechanisms leading to aHUS development. Over 75{\%} of the reported mutations cause a reduction in MCP expression, due to homozygous, compound heterozygous or heterozygous mutations. This deficiency of MCP leads to inadequate control of complement activation on endothelial cells after an initiating injury. The remaining MCP mutants are expressed, but demonstrate reduced ligand (C3b/C4b) binding capacity and cofactor activity of MCP. MCP mutations in aHUS demonstrate incomplete penetrance, indicating that additional genetic and environmental factors are required to manifest disease. MCP mutants as a cause of aHUS have a favorable clinical outcome in comparison to patients with factor H (CFH) or factor I (IF) mutations. In 90{\%} of the renal transplants performed in patients with MCP-HUS, there has been no recurrence of the primary disease, whilst >50{\%} of factor I or factor H deficient patients have had a prompt recurrence. This highlights the importance of defining and characterizing the underlying genetic defects in patients with aHUS.",
keywords = "Alternative pathway of complement (AP), Atypical hemolytic uremic syndrome (aHUS), CD46), Cofactor activity (CA), Complement factor H (CFH), Factor I (IF), Membrane cofactor protein (MCP, Renal transplantation",
author = "Anna Richards and {Kathryn Liszewski}, M. and David Kavanagh and Fang, {Celia J.} and Elizabeth Moulton and Veronique Fremeaux-Bacchi and Giuseppe Remuzzi and Marina Noris and Goodship, {Timothy H J} and Atkinson, {John P.}",
year = "2007",
month = "1",
doi = "10.1016/j.molimm.2006.07.004",
language = "English",
volume = "44",
pages = "111--122",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "1-3",

}

TY - JOUR

T1 - Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome

AU - Richards, Anna

AU - Kathryn Liszewski, M.

AU - Kavanagh, David

AU - Fang, Celia J.

AU - Moulton, Elizabeth

AU - Fremeaux-Bacchi, Veronique

AU - Remuzzi, Giuseppe

AU - Noris, Marina

AU - Goodship, Timothy H J

AU - Atkinson, John P.

PY - 2007/1

Y1 - 2007/1

N2 - The hemolytic uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. There are two general types. One occurs in epidemic form and is diarrheal associated (D + HUS). It has a good prognosis. The second is a rare form known as atypical (aHUS), which may be familial or sporadic, and has a poor prognosis. aHUS is increasingly recognized to be a disease of defective complement regulation, particularly cofactor activity. Mutations in membrane cofactor protein (MCP; CD46) that predispose to the development of aHUS were first identified in 2003. MCP is a membrane-bound complement regulator that acts as a cofactor for the factor I-mediated cleavage of C3b and C4b deposited on host cells. More than 20 different mutations in MCP have now been identified in patients with aHUS. Many of these mutants have been functionally characterized and have helped to define the pathogenic mechanisms leading to aHUS development. Over 75% of the reported mutations cause a reduction in MCP expression, due to homozygous, compound heterozygous or heterozygous mutations. This deficiency of MCP leads to inadequate control of complement activation on endothelial cells after an initiating injury. The remaining MCP mutants are expressed, but demonstrate reduced ligand (C3b/C4b) binding capacity and cofactor activity of MCP. MCP mutations in aHUS demonstrate incomplete penetrance, indicating that additional genetic and environmental factors are required to manifest disease. MCP mutants as a cause of aHUS have a favorable clinical outcome in comparison to patients with factor H (CFH) or factor I (IF) mutations. In 90% of the renal transplants performed in patients with MCP-HUS, there has been no recurrence of the primary disease, whilst >50% of factor I or factor H deficient patients have had a prompt recurrence. This highlights the importance of defining and characterizing the underlying genetic defects in patients with aHUS.

AB - The hemolytic uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. There are two general types. One occurs in epidemic form and is diarrheal associated (D + HUS). It has a good prognosis. The second is a rare form known as atypical (aHUS), which may be familial or sporadic, and has a poor prognosis. aHUS is increasingly recognized to be a disease of defective complement regulation, particularly cofactor activity. Mutations in membrane cofactor protein (MCP; CD46) that predispose to the development of aHUS were first identified in 2003. MCP is a membrane-bound complement regulator that acts as a cofactor for the factor I-mediated cleavage of C3b and C4b deposited on host cells. More than 20 different mutations in MCP have now been identified in patients with aHUS. Many of these mutants have been functionally characterized and have helped to define the pathogenic mechanisms leading to aHUS development. Over 75% of the reported mutations cause a reduction in MCP expression, due to homozygous, compound heterozygous or heterozygous mutations. This deficiency of MCP leads to inadequate control of complement activation on endothelial cells after an initiating injury. The remaining MCP mutants are expressed, but demonstrate reduced ligand (C3b/C4b) binding capacity and cofactor activity of MCP. MCP mutations in aHUS demonstrate incomplete penetrance, indicating that additional genetic and environmental factors are required to manifest disease. MCP mutants as a cause of aHUS have a favorable clinical outcome in comparison to patients with factor H (CFH) or factor I (IF) mutations. In 90% of the renal transplants performed in patients with MCP-HUS, there has been no recurrence of the primary disease, whilst >50% of factor I or factor H deficient patients have had a prompt recurrence. This highlights the importance of defining and characterizing the underlying genetic defects in patients with aHUS.

KW - Alternative pathway of complement (AP)

KW - Atypical hemolytic uremic syndrome (aHUS)

KW - CD46)

KW - Cofactor activity (CA)

KW - Complement factor H (CFH)

KW - Factor I (IF)

KW - Membrane cofactor protein (MCP

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=33751035523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751035523&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2006.07.004

DO - 10.1016/j.molimm.2006.07.004

M3 - Article

VL - 44

SP - 111

EP - 122

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 1-3

ER -